Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 4/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096294 | 0.82 | ECE1 (0.43) | TGFBR1CA2CA1ECE1KMT2A | |
| SCHEMBL2134050 | 0.81 | TGFBR1 (0.45) | TGFBR1CA2CA1MMEOR51E2 | |
| SCHEMBL27091944 | 0.81 | TGFBR1 (0.45) | TGFBR1CA2CA1MMEOR51E2 | |
| SCHEMBL1923394 | 0.80 | — | — | |
| SCHEMBL147537 | 0.80 | — | — | |
| SCHEMBL2781162 | 0.80 | KDM4E (0.47) | TGFBR1CA2CA1ECE1GGT1 | |
| SCHEMBL3937603 | 0.80 | KDM4E (0.47) | TGFBR1CA2CA1ECE1GGT1 | |
| SCHEMBL3937605 | 0.80 | KDM4E (0.47) | TGFBR1CA2CA1ECE1GGT1 | |
| SCHEMBL1418301 | 0.79 | TGFBR1 (0.43) | TGFBR1CA2CA1MMEOR51E2 | |
| SCHEMBL468807 | 0.77 | TGFBR1 (0.48) | TGFBR1MMEOR51E2GGT1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239335-B1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | AJINOMOTO KK (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8372607-B2 | Method for producing serine derivative and protein used for the same | AJINOMOTO CO., INC. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | AJINOMOTO CO., INC. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2239335-A1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | Ajinomoto Co., Inc. (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | SPR, AMD1, DAO | TGFBR1 2620/4885CA2 3712/4885CA1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.